Statistics

Total Visits

Views
Phase 2 Randomized, Noncomparative, Open-Label Study of Aflibercept and Modified Folfox6 in the First-Line Treatment of Metastatic Colorectal Cancer (Affirm)106

Select a period of time:

Number of views in the range

Views
Phase 2 Randomized, Noncomparative, Open-Label Study of Aflibercept and Modified Folfox6 in the First-Line Treatment of Metastatic Colorectal Cancer (Affirm)83

Views

Views
June 20250
July 20251
August 20250
September 20256
October 20250
November 202547
December 202529
Download CSV file
 untranslated
 untranslated

Top country views

Views
France74
United States6
Brazil1
United Kingdom1
Peru1
 

Top cities views

Views
Dallas6
Arequipa1
Marília1